Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Trial Details

NCT ID

NCT07125755

Phase

PHASE3

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

• Cisplatin

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25
• Guangzhou, Guangdong, China|23.11667,113.25
• Guilin, Guangxi, China|25.28022,110.29639
• Sanya, Hainan, China|18.25435,109.50947
• Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

• A. The pathological type is head and neck squamous cell carcinoma
• B. Radical surgery has been performed, and there are intermediary-risk factors (pT3/pT4, pN2/pN3, positive lymph nodes in the cervical IV/V region …
• C. No evidence of distant metastasis (M0).
• D. Functional status: Karnofsky scale (KPS) \> 70.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.